Lipidated peptide inhibitors of interleukin-23 receptor

Patent metadata

Field	Value
Publication number	US-12478617-B2
Application number	US-202318495457-A
Country	US
Kind code	B2
Filing date	Oct 26, 2023
Priority date	Jul 14, 2021
Publication date	Nov 25, 2025
Grant date	Nov 25, 2025

Abstract

The present invention relates to novel lipidated peptide inhibitors of the interleukin-23 receptor (IL-23R) or pharmaceutically acceptable salts, solvates and/or other forms thereof, corresponding pharmaceutical compositions, methods and/or uses of the IL-23R inhibitors for treatment of autoimmune inflammation diseases and/or related disorders.

First claim

What is claimed is:

1 . An interleukin-23 receptor inhibitor selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

2 . The interleukin-23 receptor inhibitor of claim 1 , having the following structure:

or a pharmaceutically acceptable salt thereof.

3 . The interleukin-23 receptor inhibitor of claim 1 , having the following structure:

or a pharmaceutically acceptable salt thereof.

4 . The interleukin-23 receptor inhibitor of claim 1 , having the following structure:

or a pharmaceutically acceptable salt thereof.

5 . The interleukin-23 receptor inhibitor of claim 1 , having the following structure:

or a pharmaceutically acceptable salt thereof.

6 . The interleukin-23 receptor inhibitor of claim 1 , having the following structure:

or a pharmaceutically acceptable salt thereof.

7 . The interleukin-23 receptor inhibitor of claim 1 , having the following structure:

or a pharmaceutically acceptable salt thereof.

8 . The interleukin-23 receptor inhibitor of claim 1 , having the following structure:

or a pharmaceutically acceptable salt thereof.

9 . The interleukin-23 receptor inhibitor of claim 1 , having the following structure:

or a pharmaceutically acceptable salt thereof.

10 . The interleukin-23 receptor inhibitor of claim 1 , having the following structure:

or a pharmaceutically acceptable salt thereof.

11 . The interleukin-23 receptor inhibitor of claim 1 , having the following structure:

or a pharmaceutically acceptable salt thereof.

12 . The interleukin-23 receptor inhibitor of claim 1 , having the following structure:

or a pharmaceutically acceptable salt thereof.

13 . The interleukin-23 receptor inhibitor of claim 1 , having the following structure:

or a pharmaceutically acceptable salt thereof.

14 . The interleukin-23 receptor inhibitor of claim 1 , having the following structure:

or a pharmaceutically acceptable salt thereof.

15 . The interleukin-23 receptor inhibitor of claim 1 , having the following structure:

or a pharmaceutically acceptable salt thereof.

16 . The interleukin-23 receptor inhibitor of claim 1 , having the following structure:

or a pharmaceutically acceptable salt thereof.

17 . The interleukin-23 receptor inhibitor of claim 1 , having the following structure:

or a pharmaceutically acceptable salt thereof.

18 . The interleukin-23 receptor inhibitor of claim 1 , having the following structure:

or a pharmaceutically acceptable salt thereof.

19 . The interleukin-23 receptor inhibitor of claim 1 , having the following structure:

or a pharmaceutically acceptable salt thereof.

20 . The interleukin-23 receptor inhibitor of claim 1 , having the following structure:

or a pharmaceutically acceptable salt thereof.

21 . The interleukin-23 receptor inhibitor of claim 1 , having the following structure:

or a pharmaceutically acceptable salt thereof.

22 . The interleukin-23 receptor inhibitor of claim 1 , having the following structure:

or a pharmaceutically acceptable salt thereof.

23 . The interleukin-23 receptor inhibitor of claim 1 , having the following structure:

or a pharmaceutically acceptable salt thereof.

24 . A pharmaceutical composition comprising:
(i) the interleukin-23 receptor inhibitor of claim 1 , or a pharmaceuticall

Assignees

• Janssen Biotech Inc
• Protagonist Therapeutics Inc

Inventors

• Neelamkavil Santhosh
• Sun Chengzao
• Somani Sandeep
• Barros Stephanie A
• Branca Danila
• Bhandari Ashok
• Daniel James
• Tran Tran Trung
• Frederick Brian

Classifications

• A61P37/02

  Immunomodulators · CPC title

• A61K38/00 Primary

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• C07K7/08 Primary

  having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68) · CPC title